Member Info for KingHomerJ

Well?

Wyeowye - News thats been predicted for months and years ?

Do you actually read RNS's this company is gaining strength to strength.

Also a question - how long do you think a medical device from development actually takes?

PYC have been developing a groundbreaking medical device for prostate cancer for many many years and have been funded by CRUK, NICR and its in its trails with the commercialisation agreement expected to be signed soon, as per the £350 Million MC Tabula Rasa Healthcare RNS states.

Many thanks

Wyeowye - News thats been predicted for months and years ?

Do you actually read RNS's this company is gaining strength to strength.

Also a question - how long do you think a medical device from development actually takes?

PYC have been developing a groundbreaking medical device for prostate cancer for many many years and have been funded by CRUK, NICR and its in its trails with the commercialisation agreement expected to be signed soon, as per the £350 Million MC Tabula Rasa Healthcare RNS states.

Many thanks

You are also missing the point - people are here u share research and developments of the company regardless if they are invested or not.

Positive research - people may but more or buy

Negative research - people may avoid or invested may sell.

Simple very very simple.

Companies develop and new news is readily available online and if you did your research in the first place to a point of investing then you would be familiar with these timelines, what research you would be looking for and where...

Everyone has there own strategy entry and exit / trading a share or holding for medium / long term.

As i said throwing stones at each other based on the levels of information / research posted by him / her / whoever is frankly a complete waste of time and rather childish.

I believe the propose of the boards are to share and research said company - regardless if you are invested or not.

May more people should do the research and add value to an open forum than throwing stones at each other like children.

if you don't do your own research you deserve to lose money - very simple really.

Consortium or another limited company

Siennaj how awfully nice of you.

IF you even had any idea of the new flow which is around the corner then you wouldn't even be contemplating selling any - do you know what PYC do btw?

They need big merchants - JR stated in his last interview that there were 100's of companies signed up and more and more everyday.

This clearly clearly isn't the case.

Something needs to stem the bleed and fast.

Thanks for the clarification on that.

The placement for next year is known by many and more or less confirmed by JR

JR , Mode employees and Directors are all in the group.

There IS a placing next year and it will be horrific in price unless this starts to move.

People know this so don’t want to touch it and also loads of Downwards pressure as people want to get out

Ask JR about placing - will confirm

At this rate next years placing is going to be at a horrific price.

And before anyone starts getting sensitive - ask JR

He’s often posting in the telegram group

With only 97 million shares if u know PYC this moves like crazy.

Next news will be transformational imo as it work that’s being meticulous done over the past 7-10 years is coming to a commercial agreement- namely the precious dosing application.

This will imo be fast tracked as per FDA guidelines that’s why Tabula Rasa 400 mill MC company are already integrating this into there global software DoseMerx

ONCOLOGY DEVICES AND DIAGNOSTICS
Oncology devices and diagnostics are reviewed and regulated by the Center for Devices and Radiological Health
(CDRH) in partnership with OCE. In 2020, CDRH and OCE worked toward our common goal of promoting
innovation, patient-centered oncologic approaches, and education.
Promoting innovation has always been a priority of CDRH. 2020 has seen new oncology device studies seeking
FDA oversight for indications in many cancer areas, some notable examples include: liver cancer and metastases,
lymph node mapping, differentiation of malignancies from healthy tissues and lymph nodes, novel arterial
infusion methods, and treatment of cancer therapy side-effects such as radiation dermatitis and lymphedema. We
continue to foster advancement with our Breakthrough Devices Program for certain medical devices and deviceled combination products that provide for more effective treatment or diagnosis of life-threatening or irreversibly
debilitating diseases or conditions. CDRH has granted breakthrough status to several devices for oncological
indications, including those for the detection of skin lesions and cancer

You only post on here and all it’s been is negative nonsense.

You have zero understanding of what PYC see do and have no intention of investing nor have any knowledge of it.

MR NO IDEA WHAT A TR1 is.

Bless ya.

He’s just saying a TR1 may look likely after the 250k block buys?????

Absolutely game changing for PYC

The agency is launching Project Optimus from the FDA's Oncology Center of Excellence, which will develop new guidance for cancer drug makers to test a wider range of doses early in development. The agency has long been pushing for a more thoughtful approach to dosing as cancer treatments get better and more precise.

https://www.pharmacytimes.com/view/combination-of-casirivimab-imdevimab-provides-long-term-protection-against-covid-19

Oh hello you - PYC becomes in a prime position to capitalise on these FDA Reg changes - As mentioned by Dr JM.

in his words One Material Deal can change everything.

only being played if you sell

Someone Farted when looking at the live price and accidentally executed an order

3.5 The net price of docetaxel (40 mg/ml) is £162.75 for a 0.5 ml vial and £534.75 for a 2 ml vial (excluding VAT; 'British national formulary', 50th edition). The cost per patient, assuming an average of seven cycles of treatment, would be approximately £8000.

So about 2 billion per year cost in U.K. only

pocket money to be honest in comparison to the rest of the pipeline